COVID-19: Nanomedicine Uncovers Blood-Clot Mystery

J Proteome Res. 2020 Nov 6;19(11):4364-4373. doi: 10.1021/acs.jproteome.0c00425. Epub 2020 Aug 31.


Further complications associated with infection by severe acute respiratory syndrome coronavirus 2 (a.k.a. SARS-CoV-2) continue to be reported. Very recent findings reveal that 20-30% of patients at high risk of mortality from COVID-19 infection experience blood clotting that leads to stroke and sudden death. Timely assessment of the severity of blood clotting will be of enormous help to clinicians in determining the right blood-thinning medications to prevent stroke or other life-threatening consequences. Therefore, rapid identification of blood-clotting-related proteins in the plasma of COVID-19 patients would save many lives. Several nanotechnology-based approaches are being developed to diagnose patients at high risk of death due to complications from COVID-19 infections, including blood clots. This Perspective outlines (i) the significant potential of nanomedicine in assessing the risk of blood clotting and its severity in SARS-CoV-2 infected patients and (ii) its synergistic roles with advanced mass-spectrometry-based proteomics approaches in identifying the important protein patterns that are involved in the occurrence and progression of this disease. The combination of such powerful tools might help us understand the clotting phenomenon and pave the way for development of new diagnostics and therapeutics in the fight against COVID-19.

Keywords: COVID-19; SARS-CoV-2; blood clotting; nanomedicine.

MeSH terms

  • Betacoronavirus
  • COVID-19
  • Coronavirus Infections* / complications
  • Coronavirus Infections* / physiopathology
  • Host-Pathogen Interactions
  • Humans
  • Nanomedicine*
  • Pandemics*
  • Pneumonia, Viral* / complications
  • Pneumonia, Viral* / physiopathology
  • Proteomics
  • Risk Assessment
  • SARS-CoV-2
  • Thrombosis* / diagnosis
  • Thrombosis* / virology